#USA #San Francisco #FDA #Hagens Berman #uniQure

Background on uniQure's Situation

On April 7, 2026, the well-known national shareholder rights law firm Hagens Berman announced key updates regarding its ongoing probe into uniQure N.V., traded on NASDAQ under the ticker symbol QURE. The investigations have been spurred by a series of harsh criticisms from officials at the Food and Drug Administration (FDA), accompanied by a recently filed securities class-action lawsuit related to the company's share performance. Investors who purchased uniQure shares between September 24, 2025, and October 31, 2025, are particularly affected.

Details of FDA Criticism

Particularly concerning was a critical assessment of uniQure's lead gene therapy candidate, AMT-130. According to reports from major media outlets including The Wall Street Journal and CNBC, an FDA official publicly condemned the therapy as ineffective, suggesting that uniQure's methods and comparisons were misleading. Among the notable points made during this discussion was the assertion that uniQure mischaracterized the ethical requirements surrounding controlled surgeries, drawing ire over claims of needing extensive invasive procedures when the FDA only sought minor interventions.

Moreover, the FDA also pushed back against assertions from uniQure's CEO that prior guidelines had permitted a less rigorous evaluation method. The FDA's position seemed firmly rooted in the claim that there was no previous agreement to accept uniQure's abnormal study design, which relied on historical data that had not been officially sanctioned by the agency. This lack of regulatory consensus continues to fuel investor concern and market volatility.

Class Action Lawsuit and Implications

As a direct result of the backlash, a group of investors decided to initiate a class action titled Scocco v. uniQure N.V., et al. Officials alleged that uniQure had misled its investors, suggesting that its cancer treatment was backed by proper regulatory frameworks that simply did not exist. They noted key failures, including:

• - Lack of Transparency: UniQure failed to disclose the absence of FDA consent regarding pivotal clinical trial setups which utilized historical external datasets for their AMT-130 evaluations.
• - Misleading Statements: It was implied that the company had minimized the significance of necessary control mechanisms essential for effective Phase III trials, which could severely affect the study's integrity.
• - Timeline Misrepresentations: Defendants reportedly provided guidelines that misled investors regarding the timing related to the Biologics License Application (BLA) process, only revealing substantive issues after the failures led to a staggering 49% drop in stock value on November 3, 2025.

Upcoming Deadline

Investors who experienced financial losses due to the alleged misrepresentation are facing an approaching deadline of April 13, 2026. This deadline is crucial as it concludes the timeframe wherein affected individuals may request to be appointed as a Lead Plaintiff in this pivotal lawsuit. Hagens Berman encourages those investors to submit their claims and further examination of their positions promptly.

Conclusion: A Call to Action

With the deadline looming and critical developments unfolding, it serves in the best interest of uniQure investors to remain vigilant. Efforts to understand the intricacies of the situation will likely prove invaluable in navigating the uncertain waters ahead. For those needing further insights or clarifications, Hagens Berman continues to be a resource for those impacted by this evolving narrative around uniQure N.V.